,

Recombinant Human Tumor necrosis factor receptor superfamily member 11A (TNFRSF11A), partial

Recombinant Human Tumor necrosis factor receptor superfamily member 11A (TNFRSF11A), partial — Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis. Purity >90%.

SKU: BCRECP-001791 Categories: ,

Product Specifications

Product SkuBCRECP-001791
Product DescriptionRecombinant Human Tumor necrosis factor receptor superfamily member 11A (TNFRSF11A) Protein is expressed from Mammalian cell with C-terminal hFc1-Flag-tagged. It contains 30-212aa. [Accession | Q9Y6Q6].
Uniprot No.Q9Y6Q6
Gene NamesTNFRSF11A
PurityGreater than 90% as determined by SDS-PAGE.
Expression SystemMammalian cell
Expression Region30-212aa
SpeciesHomo sapiens (Human)
Tag InfoC-terminal hFc1-Flag-tagged
Molecular weight50.0kDa
ActivityPlease contact us to obtain bioactivity data.
BufferIf the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
StorageStore at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Research AreasImmunology

Function

Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis. Its interaction with EEIG1 promotes osteoclastogenesis via facilitating the transcription of NFATC1 and activation of PLCG2. Involved in the regulation of interactions between T-cells and dendritic cells.

Biological Context

Subcellular Location: Cell membrane (Single-pass type I membrane protein)
Tissue Specificity: Ubiquitous expression with high levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland
Disease Association: Familial expansile osteolysis (FEO) : Rare autosomal dominant bone disorder characterized by focal areas of increased bone remodeling. The osteolytic lesions develop usually in the long bones during early adulthood. FEO is often associated with early-onset deafness and loss of dentition. [The disease is caused by variants affecting the gene represented in this entry] | Paget disease of bone 2, early-onset (PDB2) : A form of Paget disease, a disorder of bone remodeling characterized by increased bone turnover affecting one or more sites throughout the skeleton, primarily the axial skeleton. Osteoclastic overactivity followed by compensatory osteoblastic activity leads to a structurally disorganized mosaic of bone (woven bone), which is mechanically weaker, larger, less compact, more vascular, and more susceptible to fracture than normal adult lamellar bone. [The disease is caused by variants affecting the gene represented in this entry] | Osteopetrosis, autosomal recessive 7 (OPTB7) : A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves. OPTB7 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. OPTB7 is associated with hypogammaglobulinemia. [The disease is caused by variants affecting the gene represented in this entry]

Product Specifications

Recombinant Human Tumor necrosis factor receptor superfamily member 11A (TNFRSF11A), partial is a recombinant protein from Homo sapiens (Human), expressed in Mammalian cell, covering amino acids 30-212aa, with C-terminal hFc1-Flag-tagged tag, molecular weight 50.0kDa, purity Greater than 90% as determined by SDS-PAGE.. Suitable for ELISA and Western Blot applications.

Recommended applications depend on the target, product format, and product-specific validation data. Refer to the product datasheet or Certificate of Analysis (CoA), or contact BioCrest Sci for application guidance.

Biological Activity: Please contact us to obtain bioactivity data.

Storage: Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.

Shipping & Lead Time: Availability, shipping conditions, and estimated lead time are confirmed in the formal quotation or order confirmation based on the product format, destination, and order requirements.

Protein Biology

Function

Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis (PubMed:9878548). Its interaction with EEIG1 promotes osteoclastogenesis via facilitating the transcription of NFATC1 and activation of PLCG2 (By similarity). Involved in the regulation of interactions between T-cells and dendritic cells (By similarity)

Subcellular Location

Cell membrane (Single-pass type I membrane protein)

Disease Association

Familial expansile osteolysis (FEO) : Rare autosomal dominant bone disorder characterized by focal areas of increased bone remodeling. The osteolytic lesions develop usually in the long bones during early adulthood. FEO is often associated with early-onset deafness and loss of dentition. [The disease is caused by variants affecting the gene represented in this entry] | Paget disease of bone 2, early-onset (PDB2) : A form of Paget disease, a disorder of bone remodeling characterized by increased bone turnover affecting one or more sites throughout the skeleton, primarily the axial skeleton. Osteoclastic overactivity followed by compensatory osteoblastic activity leads to a structurally disorganized mosaic of bone (woven bone), which is mechanically weaker, larger, less compact, more vascular, and more susceptible to fracture than normal adult lamellar bone. [The disease is caused by variants affecting the gene represented in this entry] | Osteopetrosis, autosomal recessive 7 (OPTB7) : A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves. OPTB7 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. OPTB7 is associated with hypogammaglobulinemia. [The disease is caused by variants affecting the gene represented in this entry]

Tissue Specificity

Ubiquitous expression with high levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland

Subunit

Binds to the clefts between the subunits of the TNFSF11 ligand trimer to form a heterohexamer (By similarity). Part of a complex composed of EEIG1, TNFRSF11A/RANK, PLCG2, GAB2, TEC and BTK; complex formation increases in the presence of TNFSF11/RANKL (PubMed:23478294). Interacts with TRAF1, TRAF2, TRAF3, TRAF5 and TRAF6 (PubMed:9774460). Interacts (via cytoplasmic domain) with GAB2 (PubMed:15750601). Interacts (via cytoplasmic domain); with EEIG1 (via N-terminus); when in the presence of TNFSF11/RANKL (By similarity). After TNFSF11 stimulation, interacts (via IVVY motif) with STAC2; this interaction affects TNFRSF11A interaction with PLCG2 and GAB2 (By similarity)

Gene: TNFRSF11A  |  Organism: Homo sapiens  |  Synonyms: Osteoclast differentiation factor receptor; Receptor activator of NF-KB
Key Publications

Frequently Asked Questions

How do I order or inquire about this product?

Submit the Online Inquiry form with your required quantity and specifications, or email sales@biocrestsci.com. Available sizes, pricing, stock status, documentation, and estimated lead time are confirmed in the formal quotation.

What is the shipping and delivery time?

Availability, dispatch timing, shipping conditions, and delivery estimates depend on the product format, destination, and order requirements. These details are confirmed in the formal quotation or order confirmation.

How should this product be stored?

Follow the storage and handling instructions in the product-specific datasheet and Certificate of Analysis (CoA). Requirements may vary by product form and formulation; contact BioCrest Sci if product-specific guidance is needed.

What quality controls are performed on your products?

Quality-control data such as identity, purity, endotoxin level, or biological activity are provided only when specified on this product page, the datasheet, or Certificate of Analysis (CoA). Biological activity is not implied unless explicitly stated.

Shopping Cart
Scroll to Top